At SfN, some scientists described how circulating immune cells deliver aging to the mouse hippocampus; others held off parkinsonism by blocking the effects of eotaxin’s rise in blood. Human trials are starting.
The material, previously used to treat children with growth deficiencies, triggered amyloid deposition in transgenic mice.
Case study in early onset AD finds PET ligand tracks regional tau burden.
Many genes that increase risk for late-onset AD are expressed in microglia, and researchers are going cell by cell to unravel the pathways involved in the immune response to amyloid and tau.
Five years after its creation, the WDC met in London to reflect, articulate next steps, and announce more sharing of BACE trial data.
In several model systems, α-synuclein boosts oleic acid production and the fatty acid worsens α-synuclein pathology.
The awards total $52 million, divided among 17 early career investigators and nine collaborative science teams.
In patients across a range of neurodegenerative diseases, NfL ramps up in the cerebrospinal fluid. Levels are higher in those with worse disease.
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome Dash Genomics, Inc. and Abcam, which join our other exhibitors — Biogen, BioLegend, NanoString Technologies, Inc., and the Jackson Laboratory.
The daunting task of understanding how GWAS hits raise a person’s risk for AD is slowly yielding to new technologies, especially single-cell gene expression profiling. A pair of foundational studies define the diversity of mice microglia across the lifespan and after injury, and catalogue links between genetic variants and gene expression in human immune cells, respectively. These approaches lay the groundwork for new insights into the regulation of the immune response to amyloid and tau.
New in last 7 days
Latest Comments